This study evaluated whether pharmacological inhibition of KIT using the selective inhibitor THB001 could suppress mast cell activity and prevent hallmark features of allergic asthma, tested in human lung mast cells (HLMCs), isolated human bronchi, and a guinea pig house dust mite (HDM)-induced asthma model.
THB001 inhibited HLMC degranulation and survival, attenuated anti-IgE-induced bronchial contraction, prevented HDM-induced bronchoconstriction and airway hyperresponsiveness (AHR), and largely reversed mast cell expansion, airway inflammation, smooth muscle thickening, and collagen deposition in vivo; mucus-producing cells were only partially reduced.
Key findings rely on a guinea pig model, which may not fully translate to human asthma biology; the study does not include a clinical trial phase, so human efficacy and safety of THB001 remain unestablished; the mechanism driving only partial reduction of mucus-producing cells was not fully explained.
KIT inhibition with THB001 shows preclinical promise for blocking multiple structural and functional drivers of allergic asthma, but clinicians should note this remains a preclinical study — no human trial data are yet available to guide patient care.
